COSCIENS Biopharma (CSCI) moves to remove common shares from Nasdaq listing

Rhea-AI Filing Summary

COSCIENS Biopharma Inc. filed a Form 25 to remove its common shares, with no par value, from listing and/or registration on the Nasdaq Capital Market under Section 12(b) of the Securities Exchange Act of 1934.

The company certifies it has reasonable grounds to believe it meets all requirements for filing this notification, which was signed by Chief Financial Officer Giuliano La Fratta and dated August 26, 2025.

Positive

• None.

Negative

• Removal from Nasdaq Capital Market listing: COSCIENS Biopharma Inc. has filed Form 25 to remove its common shares from listing and/or registration on the Nasdaq Capital Market, a materially negative development for trading venue and potential share liquidity.

Insights

Equity markets and listing specialist

COSCIENS moves to remove its Nasdaq Capital Market listing.

COSCIENS Biopharma Inc. has filed Form 25 to remove its common shares from listing and/or registration on the Nasdaq Capital Market under Section 12(b). This formally initiates the delisting and deregistration process for that class of securities.

For investors, this typically means trading of the common shares will no longer occur on Nasdaq once the process is complete, and liquidity and visibility can change depending on any alternative trading venue. The notification is signed by the CFO on August 26, 2025, confirming the company’s intent and regulatory compliance.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number: 001-38064

COSCIENS BIOPHARMA INC.

Nasdaq Capital Market

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

c/o Norton Rose Fulbright Canada, LLP

222 Bay Street, Suite 3000, PO Box 53

Toronto, ON M5K 1E7

(Address, including zip code, and telephone number, including area code, of Issuer’s principal executive offices)

Common Shares, no par value

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

☐ 17 CFR 240.12d2-2(a)(1)

☐ 17 CFR 240.12d2-2(a)(2)

☐ 17 CFR 240.12d2-2(a)(3)

☐ 17 CFR 240.12d2-2(a)(4)

☐ Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange.¹

☒ Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with the rules of the Exchange and the requirements of 17 CFR 240.12d2-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

¹ Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

Pursuant to the requirements of the Securities Exchange Act of 1934, COSCIENS Biopharma Inc. certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

	COSCIENS Biopharma Inc.
DATE: August 26, 2025	By:	/s/ Giuliano La Fratta
		Giuliano La Fratta
		Chief Financial Officer

FAQ

What action did COSCIENS Biopharma Inc. take in its Form 25 filing?

COSCIENS Biopharma Inc. filed Form 25 to remove its common shares from listing and/or registration on the Nasdaq Capital Market under Section 12(b) of the Exchange Act. This filing starts the formal delisting and related deregistration process for that security class.

Which COSCIENS Biopharma Inc. security is affected by this Form 25?

The filing covers COSCIENS Biopharma Inc.’s common shares with no par value. These shares are currently listed on the Nasdaq Capital Market, and the Form 25 seeks to remove that listing and/or registration under Section 12(b) of the Securities Exchange Act.

On which exchange were COSCIENS Biopharma Inc. shares listed before the Form 25?

Before the Form 25 filing, COSCIENS Biopharma Inc.’s common shares were listed on the Nasdaq Capital Market. The notification relates specifically to removing this class of securities from listing and/or registration on that exchange under Section 12(b).

Who signed COSCIENS Biopharma Inc.’s Form 25 and when was it dated?

The Form 25 notification was signed on behalf of COSCIENS Biopharma Inc. by Giuliano La Fratta, the company’s Chief Financial Officer. The document is dated August 26, 2025, reflecting the company’s certification that it meets filing requirements.

What does COSCIENS Biopharma Inc. certify in its Form 25 notification?

COSCIENS Biopharma Inc. certifies that it has reasonable grounds to believe it meets all requirements for filing Form 25. This certification supports its decision to remove its common shares from listing and/or registration on the Nasdaq Capital Market under Section 12(b).